You are here: Industry Insights > biosimilars

News List

AAM praises Supreme Court Ruling granting access to biosimilars europeanpharmaceuticalreview
June 20, 2017
The Association for Accessible Medicines (AAM) applauded the US Supreme Court’s decision this week in Sandoz Inc. v. Amgen Inc. that will help speed patient access to biosimilar versions of expensive brand-name biologic medicines.
Top 10 diabetes drugs by 2016 sales fiercepharma
June 13, 2017
To say there’s a lot going on in the U.S. diabetes space right now would be an understatement.
WHO aims to increase uptake of biosimilars in poorer countries pharmafile
May 05, 2017
The WHO has announced that it will launch a project to prequalify biosimilar medicines for the treatment...
Merck divests Biosimilars business to Fresenius worldpharmanews
April 26, 2017
Merck, a leading science and technology company, has announced the divestment of its Biosimilars business to Fresenius.
Merck sells biosimilars business to Fresenius pharmatimes
April 26, 2017
Merck has divested its biosimilars business to fellow German drugmaker Fresenius in a deal potentially worth 670 million euros.
Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe cphi-online
April 25, 2017
Company receives positive CHMP opinions for biosimilars rituximab and etanercept to treat immunological diseases. Biosimilar rituximab also recommended to treat blood cancers.
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit G en-cphi
April 17, 2017
Demand for analyzers expected from emerging economies that will become manufacturing hubs, finds Frost & Sullivan's Measurement & Instrumentation team
Will the NHS force doctors to prescribe biosimilars? pharmaphorum
March 24, 2017
NHS authorities could begin to use the reimbursement system as a “stick” to ensure doctors prescribe cheaper biosimilar medicines amid varied uptake in different regions.
$100 billion of revenues up for grabs for drug manufacturers as patents for key biologics expire cphi-online
March 17, 2017
For success in the biosimilars sector, manufacturers must adopt QbD, DoE and PAT initiatives.
Which Biosimilars Will Upend the Global Market in 2017? en-cphi.cn
January 13, 2017
Biosimilars are absolutely a hotspot of the global pharmaceutical R&D field in recent years, especially in the patent cliff era. There have been biosimilars sold in the Europe since 2006, but the U.S. did not fill in gaps in system of relevant regulation

Previous page 1 2 3 4 5 6 Next page